Showing results (41-50 of 386) with videos related to

Sort By:
Pageof 39
Journal for Immunotherapy of Cancer|July 4, 2014
Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?Mizuki Nishino, Maria Gargano, Margaret Suda, et al.
The Oncologist|June 19, 2013
Ipilimumab and its toxicities: a multidisciplinary approachLeslie A Fecher, Sanjiv S Agarwala, F Stephen Hodi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2012
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibitionXiaofeng Jiang, Jun Zhou, Anita Giobbie-Hurder, et al.
Plos One|January 19, 2012
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanomaXinqi Wu, Meijun Zhu, Jonathan A Fletcher, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination TherapiesMeenal Datta, Lisa M Coussens, Hiroyoshi Nishikawa, et al.
JAMA Oncology|August 20, 2016
Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysisMizuki Nishino, Anita Giobbie-Hurder, Hiroto Hatabu, et al.
Cancer|February 13, 2013
Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanomaJeffrey S Weber, Reinhard Dummer, Veerle de Pril, et al.
Cancer Immunology Research|November 13, 2014
Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanomaJun Zhou, Meghna Gupta, Xinqi Wu, et al.
Cancer Immunity|May 16, 2003
MUC1-like tandem repeat proteins are broadly immunogenic in cancer patientsJoseph A Mollick, F Stephen Hodi, Robert J Soiffer, et al.
American Journal of Clinical Oncology|June 1, 2002
Phase II study of paclitaxel and carboplatin for malignant melanomaF Stephen Hodi, Robert J Soiffer, Jeffrey Clark, et al.
Pageof 39